Pertussis Vaccine Market Size Projected To Increase From $5.81 Billion To $6.82 Billion During The Forecast Period
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Pertussis Vaccine Market Value Expansion And Long-Term Growth Outlook
The size of the pertussis vaccine market has experienced consistent expansion in recent times. From $5.65 billion in 2025, it is projected to reach $5.82 billion by 2026, reflecting a compound annual growth rate (CAGR) of 2.9%. Factors driving historical growth include extensive immunization coverage among children, government-sponsored nationwide vaccination initiatives, past episodes of whooping cough outbreaks, the integration of the pertussis vaccine into standard immunization protocols, and the accessibility of whole-cell vaccines.
The pertussis vaccine market is anticipated to experience consistent expansion over the coming years, projected to reach $6.82 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.1%. This forecasted growth is driven by factors such as heightened awareness regarding adult pertussis vaccination, increased recommendations for maternal immunization, improvements in vaccine safety and effectiveness, broader healthcare access in developing nations, and the advancement of combination vaccine formulations. Key trends shaping this period include the growing preference for acellular pertussis vaccines, a heightened emphasis on booster immunization programs, the development of more combined vaccines containing pertussis elements, expanded vaccination efforts targeting adults and pregnant women, and reinforced government-led immunization campaigns.
Download A Free Sample Report For Comprehensive Market Insights:
Pertussis Vaccine Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growth of the pertussis vaccine market is being propelled forward by an increase in childbirth rates. Childbirth refers to the process of delivering a baby, signaling the end of a pregnancy where a fetus develops inside the mother’s womb and the start of a new life outside it. This vaccine is mainly administered to children as it shields them from whooping cough and other serious, potentially fatal illnesses. As an example, a January 2023 report from the Centers for Disease Control and Prevention, a U.S.-based national public health agency, revealed that registered births in the United States rose by 1% to 3,664,292 compared to the previous year, 2022. Consequently, the rising number of childbirths is fueling expansion in the pertussis vaccine market.
Pertussis Vaccine Market Segment Analysis Highlighting Growth Areas
The pertussis vaccine market covered in this report is segmented –
1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine
2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine
3) By Application: Children, Adults, Infants
4) By End-User: Vaccination Centers, Hospitals, Clinics
Subsegments:
1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP
2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine
Pertussis Vaccine Market Innovation Trends Driving Future Development
Leading players in the pertussis vaccine industry are concentrating on the creation of cutting-edge immunization strategies and obtaining official approvals to improve protection for both mothers and their newborns against whooping cough. These initiatives seek to boost vaccine availability, extend authorized usage during pregnancy, and decrease pertussis-related illness rates in infants. For example, in January 2023, Sanofi S.A., a biopharmaceutical firm headquartered in France, secured approval from the U.S. FDA for an expanded application of its Adacel (Tdap) vaccine during the third trimester of pregnancy. This move allows maternal vaccination to safeguard infants under two months old—the group most vulnerable to severe pertussis. By immunizing pregnant individuals, healthcare providers can ensure that protective antibodies are transferred to the baby prior to delivery, offering early-life defense against pertussis and filling the immunity gap until the infant’s own vaccinations begin.Leading companies in the pertussis vaccine market are prioritizing the development of advanced immunization methods and obtaining regulatory clearances to improve protection for both mothers and infants against whooping cough. These strategies aim to increase vaccine accessibility, broaden recommended usage during pregnancy, and lower pertussis-related health complications among newborns. For instance, in January 2023, Sanofi S.A., a biopharmaceutical company based in France, received U.S. FDA approval to extend the use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, allowing maternal immunization to protect infants under two months old who face the greatest risk of severe pertussis infection. This approval empowers healthcare providers to vaccinate pregnant individuals, facilitating the transfer of protective antibodies to the baby before birth. Consequently, infants gain early immunity against pertussis, closing the protection gap until they can receive their own vaccinations.
Pertussis Vaccine Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the pertussis vaccine market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Sanofi Pasteur SA, CSL Limited, Serum Institute of India, Biological E. Limited, Bharat Biotech International Limited, Panacea Biotec Limited, PT Bio Farma, Walvax Biotechnology Co. Ltd., Beijing Minhai Biotechnology Co. Ltd., Wuhan Institute of Biological Products, Changchun Changsheng Life Sciences, Changsheng Bio-Technology Co. Ltd., Chiron Corporation, Sinovac Biotech Ltd., Takeda Pharmaceutical Company, Novartis AG, Johnson & Johnson
Access The Complete Pertussis Vaccine Market Report:
Pertussis Vaccine Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the pertussis vaccine market in 2025. The regions covered in the pertussis vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
